Rational drug discovery design approaches for treating Parkinson's disease

Expert Opinion on Drug Discovery

Volumn 10, Issue 7, 2015, Pages 713-741

  Van Der Schyf, Cornelis J ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Drug discovery; Motor deficits; Neurodegeneration; Neuroprotection; Neurorescue; Non motor symptoms; Parkinson's disease; Pathoetiological pathways

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITOR; ADENOSINE A2A RECEPTOR ANTAGONIST; BENSERAZIDE PLUS LEVODOPA; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ENZYME INHIBITOR; FIPAMEZOLE; GANGLIOSIDE; ISTRADEFYLLINE; LADOSTIGIL; LEVODOPA DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU 120; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; OPICAPONE; PARDOPRUNOX; PIMAVANSERIN; RIVASTIGMINE; SAFINAMIDE; TAK 065; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE; XP 21279; ZONISAMIDE; ANTIPARKINSON AGENT;

DEGENERATIVE DISEASE; DISEASE COURSE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HUMAN; MOLECULAR PATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84932106482     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1041495     Document Type: Review

References (162)

1. Xie A, Gao J, Xu L, Meng D. Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res Int 2014;2014:648740
2. Savica R, Grossardt BR, Bower JH, et al. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013;70(7):859-66
3. Danila O, Hirdes JP, Maxwell CJ, et al. Prevalence of neurological conditions across the continuum of care based on interRAI assessments. BMC Health Serv Res 2014;14:29
4. Stovner LJ, Hoff JM, Svalheim S, Gilhus NE. Neurological disorders in the Global Burden of Disease 2010 study. Acta Neurol Scand Suppl 2014;198:1-6
5. Singhal BS, Khadilkar SV. Neurology in the developing world. Handb Clin Neurol 2014;121:1773-82
6. Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014;384(9942):545-55
7. Youdim MB, Geldenhuys WJ, Van der Schyf CJ. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat Disord 2007;13(Suppl 3):S281-91
8. Van der Schyf CJ, Geldenhuys WJ. Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int Rev Neurobiol 2011;100:107-25
9. Geldenhuys WJ, Van der Schyf CJ. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 2013;8(2):115-29
10. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992;340(8812):186
11. Pearce RKB, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995;10(3):283-7
12. Mayeux R, Stern Y, Williams JBW. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143(6):756-9
13. Van der Schyf CJ, Squier GJ, Coetzee WA. Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol Res Commun 1986;18(5):407-17
14. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology 2010;75(20):1773-9
15. Manni R, Terzaghi M, Repetto A, et al. Complex paroxysmal nocturnal behaviors in Parkinson's disease. Mov Disord 2010;25(8):985-90
16. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorderneurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010;1184:15-54
17. Poewe W. Dysautonomia and cognitive dysfunction in Parkinson's disease. Mov Disord 2007;22(Suppl 17):S374-8
18. Kulisevsky J, Pagonbarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008;23(13):1889-96
19. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211
20. Shtilbans A, Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012;25(4):460-5
21. Halliday GM, Pond SM, Cartwright H, et al. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol 1999;158(1):155-63
22. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's Disease. Parkinsons Dis 2011;2011:708404
23. Schapira A, Bate G, Kirkpatrick P. Rasagiline. Nature Rev 2005;4:625-6
24. Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamineinduced degeneration of nigrostriatal neurons. Brain Res 1996;742:80-8
25. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005;23:193-206
26. Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MB. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 2006;15(8):873-86
27. Van der Schyf CJ, Geldenhuys WJ. Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int Rev Neurobiol 2011;100:107-25
28. Van der Schyf CJ, Youdim MB. Multifunctional drugs as neurotherapeutics. Neurotherapeutics 2009;6(1):1-3
29. Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr Med Chem 2013;20(13):1662-72
30. Lockman JA, Geldenhuys WJ, Jones-Higgins MR, et al. NGP1-01, a multi-targeted polycyclic cage amine, attenuates brain endothelial cell death in iron overload conditions. Brain Res 2012;13(1489):133-9
31. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51(3):347-72
32. Van der Schyf CJ. The use of multitarget drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol 2011;4(3):293-8
33. Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the nondopaminergic pipeline? Neurotherapeutics 2014;11(1):34-46
34. Trippier PC, Jansen Labby K, Hawker DD, et al. Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem 2013;56(8):3121-47
35. Geldenhuys WJ, Lockman PR, McAfee JH, et al. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg Med Chem Lett 2004;14(12):3085-92
36. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004;10(Suppl):S2-9
37. Petrucci S, Consoli F, Valente EM. Parkinson disease genetics: a "continuum" from mendelian to multifactorial inheritance. Curr Mol Med 2014. [Epub ahead of print]
38. Mitsui J, Tsuji S. Genomic aspects of sporadic neurodegenerative diseases. Biochem Biophys Res Commun 2014;452(2):221-5
39. Kay CT, Shu-Leong H. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Transl Neurodegener 2013;2:19
40. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408
41. Fabbrini G, Abbruzzese G, Marconi S, Zappia M. Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol 2012;35(3):134-40
42. Marconi S, Zwingers T. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. Eur Rev Med Pharmacol Sci 2014;18(13):1879-82
43. McCormack PL. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. CNS Drugs 2014;28(11):1083-97
44. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010;92(3):330-44
45. Youdim MBH, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness Br J Pharmacol 2006;147(Suppl 1):S287-S296
46. Baker GB, Sowa B Jr, Todd KG. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci 2007;32(5):313-15
47. Maragos WF, Young KL, Altman CS, et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgylinetreated rats and MAO-A deficient mice. Neurochem Res 2004;29(4):741-6
48. Dézsi L, Vécsei L. Safinamide for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2014;23(5):729-42
49. Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol 2003;26(4):213-17
50. Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014;29(2):229-37
51. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012;13(4):483-94
52. Maruyama W, Weinstock M, Youdim MB, et al. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(Npropargyl)-( 3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterasemonoamine oxidase inhibitor. Neurosci Lett 2003;341(3):233-6
53. Sagi Y, Weinstock M, Youdim MB, et al. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003;86(2):290-297
54. Stone TW, Burton NR. NMDA receptors and ligands in the vertebrate CNS. Prog Neurobiol 1988;30(4):333-68
55. Koutsilieri E, Riederer P. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat Disord 2007;13(Suppl 3):S329-31
56. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013;14(6):383-400
57. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003(2):CD003467
58. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005;25(13):3312-22
59. Geldenhuys WJ, Malan SF, Murugesan T, et al. Synthesis and biological evaluation of pentacyclo [5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease. Bioorg Med Chem 2004;12(7):1799-806
60. Malan SF, Dyason K, Wagenaar B, et al. The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo [6.5.0.0(3,7).0(4,12).0(5,10).0(9,13] tridecane. Arch Pharm (Weinheim) 2003;336(2):127-33
61. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003(1):CD003468
62. Müller T. Current status of safinamide for the drug portfolio of Parkinson's disease therapy. Expert Rev Neurother 2013;13(9):969-77
63. Podurgiel S, Collins-Praino LE, Yohn S, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav 2013;105:105-11
64. Cuello AC. Gangliosides, NGF, brain aging and disease: a mini-review with personal reflections. Neurochem Res 2012;37(6):1256-60
65. Ryu BR, Choi DW, Hartley DM, et al. Attenuation of cortical neuronal apoptosis by gangliosides. J Pharmacol Exp Ther 1999;290(2):811-16
66. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28(13):1838-46
67. Bezard E, Pioli EY, Li Q, et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 2014;29(8):1074-9
68. Rascol O, Fox S, Gasparini F. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopainduced dyskinesias. Parkinsonism Relat Disord 2014;20(9):947-56
69. Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharmacol 2010;66(2):119-25
70. Nissinen E. Introductory remarks: Catechol-O-methyltransferase inhibition - an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition. Int Rev Neurobiol 2010;95:1-5
71. Goetz CG. Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology 1998;50(5 Suppl 5):S26-30
72. Truong DD. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging 2009;4:109-13
73. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000;55(11 Suppl 4):S33-7
74. Müller T. Entacapone. Expert Opin Drug Metab Toxicol 2010;6(8):983-93
75. Brusa L, Pierantozzi M, Bassi A, et al. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. Neurol Sci 2004;5(2):53-6
76. Rocha JF, Almeida L, Falcão A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013;76(5):763-75
77. Ferreira JJ, Rocha JF, Santos A. The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo and non-inferiority vs. entacapone [abstract]. Mov Disord 2012;27(Suppl 1):365
78. Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson's disease. Expert Rev Neurother 2014;14(2):143-9
79. Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord 2015;30(1):37-44
80. Lennert B, Bibeau W, Farrelly E, et al. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits 2012;5(6):347-58
81. Santos-García D, Prieto-Formoso M, de la Fuente-Fernández R. Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson's disease. J Neurol Sci 2012;318(1-2):90-3
82. Nyholm D. Duodopa- treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18(8):916-29
83. Nyholm D, Lewander T, Gomes-Trolin C, et al. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol 2012;35(3):111-17
84. Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopalevodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 2014;20(12):1335-40
85. Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014;20(2):142-8
86. Metman LV, Stover N, Cowles V, et al. Improved motor performance associated with smoother levodopa timeconcentration profiles with DM-1992, a gastroretentive, extended-release carbidopa/levodopa tablet, in patients with advanced Parkinson's disease. Neurology 2014;82:10 Suppl P7.082
87. Pereira RL, Paim CS, Barth AB, et al. Levodopa microparticles for pulmonary delivery: photodegradation kinetics and LC stability-indicating method. Pharmazie 2012;67(7):605-10
88. Lee KE, Choi YJ, Oh BR, et al. Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems. Int J Pharm 2013;456(2):432-6
89. LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014;29(1):75-82
90. Schiffmann SN, Dassesse D, d'Alcantara P, et al. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology 2003;61(11 Suppl 6):S24-9
91. Rosin DL, Hettinger BD, Lee A, et al. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003;61(11 Suppl 6):S12-18
92. Filip M, Zaniewska M, Frankowska M, et al. The importance of the adenosine A (2A) receptor-dopamine D(2) receptor interaction in drug addiction. Curr Med Chem 2012;19(3):317-55
93. Bagetta V, Picconi B, Marinucci S, et al. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 2011;31(35):12513-22
94. Rivera-Oliver M, Díaz-Ríos M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 2014;101(1-2):1-9
95. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001;18(11):797-806
96. Xu K, Xu YH, Chen JF, et al. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010;167(2):475-81
97. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000;20(20):7782-9
98. Cerri S, Levandis G, Ambrosi G, et al. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. J Neuropathol Exp Neurol 2014;73(5):414-24
99. Perez-Lloret S, Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Expert Opin Pharmacother 2014;15(8):1097-107
100. Factor SA, Wolski K, Togasaki DM, et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord 2013;28(6):817-20
101. Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13(8):767-76
102. Ongini E, Monopoli A, Cacciari B, et al. Selective adenosine A2A receptor antagonists. Farmaco 2001;56(1-2):87-90
103. Wang Z, Che PL, Du J, et al. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One 2010;5(11):e13883
104. Piersanti G, Bartoccini F, Lucarini S, et al. Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease. J Med Chem 2013;56(13):5456-63
105. Pinna A. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014;28(5):455-74
106. Ramlackhansingh AF, Bose SK, Ahmed I, et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011;76(21):1811-16
107. Trevitt J, Kawa K, Jalali A, et al. Differential effects of adenosine antagonists in two models of parkinsonian tremor. Pharmacol Biochem Behav 2009;94(1):24-9
108. Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and nonmotor symptoms. J Alzheimers Dis 2010;20(Suppl 1):S205-20
109. Shen HY, Chen JF. Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition. Curr Neuropharmacol 2009;7(3):195-206
110. Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson's disease. Int Rev Neurobiol 2014;119:71-86
111. Bartus RT, Weinberg MS, Samulski RJ. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014;22(3):487-97
112. Lewis TB, Glasgow JN, Glandon AM, et al. Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy. PLoS One 2010;5(9):e12672
113. Chtarto A, Bockstael O, Tshibangu T, et al. A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol 2013;76(2):217-32
114. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80(18):1698-701
115. Diaz-Nido J. NLX-P101, an adenoassociated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs 2010;11(7):813-22
116. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383(9923):1138-46
117. Kang S, Cooper G, Dunne SF, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun 2012;3:1146
118. Tai CH, Yang YC, Pan MK, et al. Modulation of subthalamic T-type Ca(2 +) channels remedies locomotor deficits in a rat model of Parkinson disease. J Clin Invest 2011;121(8):3289-305
119. Kiewert C, Hartmann J, Stoll J, et al. NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligandoperated calcium channels. Neurochem Res 2006;31(3):395-9
120. Grover ND, Limaye RP, Gokhale DV, et al. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian J Pharmacol 2013;45(6):547-55
121. Murata M. Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc) 2010;46(4):251-8
122. McFarland K, Price DL, Bonhaus DW. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 2011;22(7):681-92
123. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013;123(12):4986-91
124. Gerlach M, Halley P, Riederer P, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of a(2) adrenergic mechanisms. J Neural Transm 2013;120(1):31-6
125. Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79(2):163-9
126. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50(4):433440
127. Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an openlabel, randomized study. Clin Neuropharmacol 2014;37(1):9-16
128. Bar-Am O, Weinreb O, Amit T, et al. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 2009;37(2):135-45
129. Youdim MB, Kupershmidt L, Amit T, et al. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord 2014;20(Suppl 1):S132-6
130. Weinreb O, Amit T, Bar-Am O, et al. The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci 2008;13:5131-7
131. Raspail C, Graindorge M, Moreau Y. 4-hydroxyphenylpyruvate dioxygenase catalysis: identification of catalytic residues and production of a hydroxylated intermediate shared with a structurally unrelated enzyme. J Biol Chem 2011;286(29):26061-70
132. Xu YL, Lin HY, Cao RJ, et al. Pyrazolone-quinazolone hybrids: a novel class of human 4-hydroxyphenylpyruvate dioxygenase inhibitors. Bioorg Med Chem 2014;22(19):5194-211
133. Tan L, Ge H, Tang J, et al. Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. Behav Brain Res 2015;279:274-82
134. Wang T, Huang XJ, Van KC, et al. Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. J Neurotrauma 2014;31(4):370-377
135. Waters S, Ponten H, Edling M, et al. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm 2014;121(11):1337-47
136. Visanji NP, Orsi A, Johnston TH, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008;22(7):2488-97
137. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 2015;11(1):25-40
138. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66(12):1460-8
139. Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009;25(12):2977-87
140. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa in parkinson disease progression. J Am Med Assoc 2002;287:1653-61
141. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging 2012;7:83-8
142. Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson' s disease with ropinirole versus levodopa: the REAL- PET study. Ann Neurol 2003;54:93-101
143. Stocchi F, Radicati FG, Torti M. Drug safety evaluation of ropinirole prolonged release. Expert Opin Drug Saf 2014;13(3):383-9
144. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinsona? s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12:747-755
145. Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18(4):370-6
146. Bronzova J, Sampaio C, Hauser RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010;25(6):738-46
147. Sampaio C, Bronzova J, Hauser RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011;26(8):1464-76
148. Risgaard R, Jensen M, Jorgensen M, et al. Synthesis and SAR study of a novel series of dopamine receptor agonists. Bioorg Med Chem 2014;22(1):381-92
149. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29(13):1583-90
150. Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One 2015;10(2):e0116820
151. Chen JJ. Parkinson's disease: healthrelated quality of life, economic cost, and implications of early treatment. Am J Manag Care 2010;16(Suppl Implications):S87-93
152. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010;81(9):1008-13
153. Grandas F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease. Expert Rev Neurother 2013;13(12):1343-53
154. Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2013;19(12):1073-8
155. Benitez A, Edens H, Fishman J, et al. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Ann N Y Acad Sci 2014;1329:45-66
156. Jucaite A, Svennigsson P, Rinne J, et al. Effect of the myeloperoxidase inhibitor AZD3241 on translocator protein binding in brain - A positron emission tomography study in patients with Parkinson's disease. Mov Disord 2014;29(Suppl 1):662
157. Van Hilten JJ, Ramaker CC, Stowe R, et al. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev 2007(4):CD002258
158. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 2004;64(18):2125-41
159. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29(2):80-6
160. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21(8):677-92
161. Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs 2003;17:729-62
162. Foley P, Gerlach M, Youdim MBH, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000;6:25-47